{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T10:39:27Z","timestamp":1788863967484,"version":"build-2803163510"},"reference-count":36,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,6]]},"abstract":"<jats:title>Summary<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background and objectives<\/jats:title>\n                    <jats:p>The role of thrombophilia in failing arteriovenous fistula (AVF) among patients with ESRD undergoing hemodialysis is not established. This study aimed to assess whether AVF primary patency is associated with thrombophilia and coagulation abnormalities.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design, setting, participants, &amp; measurements<\/jats:title>\n                    <jats:p>This observational study screened 219 patients between 2002 and 2004 for thrombophilia before AVF surgery. Thrombophilia included factor V Leiden and prothrombin G20210A mutations, protein C and antithrombin activities, and protein S. Coagulation abnormalities included high factor VIII:C, homocysteine, fibrinogen, and D-dimer levels; presence of antiphospholipid antibodies; and short thrombin time. We reviewed patient charts for comorbid conditions, AVF maturation and interventions, kidney transplantation, and patient survival (mean follow-up duration, 3.6 [range, 2.3\u20135.8] years). Primary patency from the AVF placement and functional primary patency from the first AVF cannulation were analyzed with Kaplan-Meier and Cox proportional hazards models.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Thrombophilia was present in 9% of the patients, and coagulation abnormalities occurred in 77%. One-year primary patency was 68%; 46% of the AVF failures occurred before the initiation of hemodialysis. Female sex (hazard ratio [HR], 2.6; 95% confidence interval [CI], 1.7\u20134.1) and thrombophilia (HR, 2.2; 95% CI, 1.2\u20134.2) were independent risk factors for loss of primary patency. Thrombophilia mutations or low antithrombin level (HR, 3.8), female sex (HR, 2.5), and diabetes (HR, 1.9) were associated with shortened functional primary patency of AVF.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Against the background of frequent coagulation abnormalities, thrombophilia and female sex predispose patients with ESRD to access failure, mostly due to thrombosis or stenosis.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2215\/cjn.03860412","type":"journal-article","created":{"date-parts":[[2013,2,15]],"date-time":"2013-02-15T01:10:20Z","timestamp":1360890620000},"page":"962-968","source":"Crossref","is-referenced-by-count":82,"title":["Thrombophilia and Arteriovenous Fistula Survival in ESRD"],"prefix":"10.2215","volume":"8","author":[{"given":"Birgitta","family":"Salmela","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jari","family":"Hartman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seija","family":"Peltonen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anders","family":"Alb\u00e4ck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riitta","family":"Lassila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-12-20230811","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1681\/ASN.V74523","article-title":"Hemodialysis vascular access morbidity.","volume":"7","author":"Feldman","year":"1996","journal-title":"J Am Soc Nephrol"},{"key":"R2-12-20230811","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1681\/ASN.2004110999","article-title":"Thrombophilia and the risk for hemodialysis vascular access thrombosis.","volume":"16","author":"Knoll","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"R3-12-20230811","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1681\/ASN.2005050615","article-title":"Hemodialysis vascular access dysfunction: A cellular and molecular viewpoint.","volume":"17","author":"Roy-Chaudhury","year":"2006","journal-title":"J Am Soc Nephrol"},{"key":"R4-12-20230811","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1093\/oxfordjournals.ndt.a027357","article-title":"Resistance to activated protein C (APC): Mutation at Arg506 of coagulation factor V and vascular access thrombosis in haemodialysis patients.","volume":"11","author":"F\u00f6dinger","year":"1996","journal-title":"Nephrol Dial Transplant"},{"key":"R5-12-20230811","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/S1072-7515(99)00086-1","article-title":"Thrombotic complications resulting from hypercoagulable states in chronic hemodialysis vascular access.","volume":"189","author":"LeSar","year":"1999","journal-title":"J Am Coll Surg"},{"key":"R6-12-20230811","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1046\/j.1523-1755.1999.00258.x","article-title":"Hyperhomocysteinemia, anticardiolipin antibody status, and risk for vascular access thrombosis in hemodialysis patients.","volume":"55","author":"Manns","year":"1999","journal-title":"Kidney Int"},{"key":"R7-12-20230811","first-page":"116","article-title":"A large prospective survey of anti-cardiolipin antibodies in chronic hemodialysis patients.","volume":"51","author":"Valeri","year":"1999","journal-title":"Clin Nephrol"},{"key":"R8-12-20230811","first-page":"428","article-title":"IgM anticardiolipin antibodies are associated with stenosis of vascular access in hemodialysis patients but do not predict thrombosis.","volume":"56","author":"Adler","year":"2001","journal-title":"Clin Nephrol"},{"key":"R9-12-20230811","doi-asserted-by":"crossref","first-page":"2030","DOI":"10.1016\/S0041-1345(02)02840-3","article-title":"Role of genetic mutations in vascular access thrombosis among hemodialysis patients waiting for renal transplantation.","volume":"34","author":"Ata\u00e7","year":"2002","journal-title":"Transplant Proc"},{"key":"R10-12-20230811","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1053\/j.ajkd.2005.01.004","article-title":"Hyperhomocysteinemia and arteriovenous fistula thrombosis in hemodialysis patients.","volume":"45","author":"Mallamaci","year":"2005","journal-title":"Am J Kidney Dis"},{"key":"R11-12-20230811","doi-asserted-by":"crossref","first-page":"2700","DOI":"10.1093\/ndt\/gfq791","article-title":"Thrombophilic factors in stage V chronic kidney disease patients are largely corrected by renal transplantation.","volume":"26","author":"Ghisdal","year":"2011","journal-title":"Nephrol Dial Transplant"},{"key":"R12-12-20230811","doi-asserted-by":"crossref","first-page":"714","DOI":"10.2215\/CJN.02950707","article-title":"Hemodialysis arteriovenous fistula patency revisited: Results of a prospective, multicenter initiative.","volume":"3","author":"Huijbregts","year":"2008","journal-title":"Clin J Am Soc Nephrol"},{"key":"R13-12-20230811","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1016\/S0140-6736(98)10266-0","article-title":"Venous thrombosis: a multicausal disease.","volume":"353","author":"Rosendaal","year":"1999","journal-title":"Lancet"},{"key":"R14-12-20230811","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.ejvs.2004.03.027","article-title":"Prevalence and risk of thrombophilia defects in vascular patients.","volume":"28","author":"Vig","year":"2004","journal-title":"Eur J Vasc Endovasc Surg"},{"key":"R15-12-20230811","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1023\/B:THRO.0000036027.39353.70","article-title":"Evolving concepts in the triad of atherosclerosis, inflammation and thrombosis.","volume":"17","author":"Corti","year":"2004","journal-title":"J Thromb Thrombolysis"},{"key":"R16-12-20230811","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1046\/j.1538-7836.2003.00261.x","article-title":"Inflammation and thrombosis.","volume":"1","author":"Esmon","year":"2003","journal-title":"J Thromb Haemost"},{"key":"R17-12-20230811","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1055\/s-2006-939554","article-title":"Inflammation and the activated protein C anticoagulant pathway.","volume":"32","author":"Esmon","year":"2006","journal-title":"Semin Thromb Hemost"},{"key":"R18-12-20230811","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1001\/jama.293.14.1737","article-title":"Cardiovascular mortality risk in chronic kidney disease: Comparison of traditional and novel risk factors.","volume":"293","author":"Shlipak","year":"2005","journal-title":"JAMA"},{"key":"R19-12-20230811","doi-asserted-by":"crossref","first-page":"2975","DOI":"10.1093\/eurheartj\/ehl402","article-title":"Renal function and cardiovascular mortality in elderly men: The role of inflammatory, procoagulant, and endothelial biomarkers.","volume":"27","author":"Wannamethee","year":"2006","journal-title":"Eur Heart J"},{"key":"R20-12-20230811","first-page":"CR55","article-title":"Validity of plasma fibrinogen, D-dimer, and the von Willebrand factor as markers of cardiovascular morbidity in patients on chronic hemodialysis.","volume":"12","author":"Kirmizis","year":"2006","journal-title":"Med Sci Monit"},{"key":"R21-12-20230811","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1046\/j.1523-1755.1999.00515.x","article-title":"Predictors of adequacy of arteriovenous fistulas in hemodialysis patients.","volume":"56","author":"Miller","year":"1999","journal-title":"Kidney Int"},{"key":"R22-12-20230811","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1046\/j.1523-1755.2003.00740.x","article-title":"Gender differences in outcomes of arteriovenous fistulas in hemodialysis patients.","volume":"63","author":"Miller","year":"2003","journal-title":"Kidney Int"},{"key":"R23-12-20230811","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1111\/j.1525-139X.2006.00218.x","article-title":"Vascular access outcomes and medication use: a USRDS study.","volume":"19","author":"Yevzlin","year":"2006","journal-title":"Semin Dial"},{"key":"R24-12-20230811","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1067\/mva.2001.117890","article-title":"Vascular access survival and incidence of revisions: A comparison of prosthetic grafts, simple autogenous fistulas, and venous transposition fistulas from the United States Renal Data System Dialysis Morbidity and Mortality Study.","volume":"34","author":"Gibson","year":"2001","journal-title":"J Vasc Surg"},{"key":"R25-12-20230811","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1024\/0301-1526\/a000018","article-title":"Determinants of haemodialysis access survival.","volume":"39","author":"Diehm","year":"2010","journal-title":"Vasa"},{"key":"R26-12-20230811","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.2215\/CJN.09441209","article-title":"Risk factors associated with patency loss of hemodialysis vascular access within 6 months.","volume":"5","author":"Monroy-Cuadros","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"key":"R27-12-20230811","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1001\/jama.295.3.306","article-title":"Aspirin for the primary prevention of cardiovascular events in women and men: A sex-specific meta-analysis of randomized controlled trials.","volume":"295","author":"Berger","year":"2006","journal-title":"JAMA"},{"key":"R28-12-20230811","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1093\/ndt\/14.10.2474","article-title":"Combination of APC resistance and acquired protein S deficiency in a haemodialysis patient with recurrent A-V shunt thrombosis.","volume":"14","author":"Mitsiev","year":"1999","journal-title":"Nephrol Dial Transplant"},{"key":"R29-12-20230811","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/S0741-5214(03)00321-5","article-title":"Hypercoagulable states and antithrombotic strategies in recurrent vascular access site thrombosis.","volume":"38","author":"O\u2019Shea","year":"2003","journal-title":"J Vasc Surg"},{"key":"R30-12-20230811","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1046\/j.1525-139x.2000.00012.x","article-title":"Antithrombotic agents and the prevention of access thrombosis.","volume":"13","author":"Kaufman","year":"2000","journal-title":"Semin Dial"},{"key":"R31-12-20230811","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1097\/01.ASN.0000081661.10246.33","article-title":"Randomized controlled trial of clopidogrel plus aspirin to prevent hemodialysis access graft thrombosis.","volume":"14","author":"Kaufman","year":"2003","journal-title":"J Am Soc Nephrol"},{"key":"R32-12-20230811","doi-asserted-by":"crossref","first-page":"2164","DOI":"10.1001\/jama.299.18.2164","article-title":"Effect of clopidogrel on early failure of arteriovenous fistulas for hemodialysis: A randomized controlled trial.","volume":"299","author":"Dember","year":"2008","journal-title":"JAMA"},{"key":"R33-12-20230811","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1056\/NEJMoa0805840","article-title":"Effect of dipyridamole plus aspirin on hemodialysis graft patency.","volume":"360","author":"Dixon","year":"2009","journal-title":"N Engl J Med"},{"key":"R34-12-20230811","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1681\/ASN.2010060582","article-title":"Use of aspirin associates with longer primary patency of hemodialysis grafts.","volume":"22","author":"Dixon","year":"2011","journal-title":"J Am Soc Nephrol"},{"key":"R35-12-20230811","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.2215\/CJN.00130108","article-title":"Consistent aspirin use associated with improved arteriovenous fistula survival among incident hemodialysis patients in the dialysis outcomes and practice patterns study.","volume":"3","author":"Hasegawa","year":"2008","journal-title":"Clin J Am Soc Nephrol"},{"key":"R37-12-20230811","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1111\/j.1365-2141.2012.09134.x","article-title":"Elevated factor VIII levels and risk of venous thrombosis.","volume":"157","author":"Jenkins","year":"2012","journal-title":"Br J Haematol"}],"container-title":["Clinical Journal of the American Society of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/01277230-201306000-00012","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T13:43:03Z","timestamp":1786369383000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/01277230-201306000-00012"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,6]]},"references-count":36,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2013]]}},"URL":"https:\/\/doi.org\/10.2215\/cjn.03860412","relation":{},"ISSN":["1555-9041"],"issn-type":[{"value":"1555-9041","type":"print"}],"subject":[],"published":{"date-parts":[[2013,6]]}}}